Bevacizumab plus paclitaxel/carboplatin is predicted to become the clinical gold-standard for advanced ovarian cancer in 2011

Source: Inpharma, Volume 1, Number 1637, 2008-05-10 , pp. 2-2(1)

Publisher: Adis International

Keywords: Bevacizumab, therapeutic use; Bristol-Myers-Squibb; Carboplatin, therapeutic use; Chugai-Pharmaceutical; Decision-Resources; Genentech; Healthcare-news; Ovarian-cancer, treatment; Paclitaxel, therapeutic use; Pharmaceutical-industry; Prescribing; Roche

Document Type: Short communication

Publication date: 2008-01-01

• In this: publication
• By this: publisher
• In this Subject: Pharmacology

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers